Abstract:Highlights • DZSM improved cognitive impairment, neuronal loss, and synaptic dysfunction in AD rats. • DZSM improved mitochondrial dysfunction by activating mitophagy and inhibiting Drp1-mediated mitochondrial fission. • Aβ 42 significantly reduced the memory ability and significantly reduced synaptic activities. • DZSM significantly increased the frequency and amplitude of the synaptic transmission, both the frequency and amplitude. Emerging research suggests a potential association of progression of Alzheimer's disease (AD) with alterations in synaptic currents and mitochondrial dynamics. However, the specific associations between these pathological changes remain unclear. In this study, we utilized Aβ 42 -induced AD rats and primary neural cells as in vivo and in vitro models. The investigations included behavioural tests, brain magnetic resonance imaging (MRI), liquid chromatography-tandem mass spectrometry(UPLC-MS/MS) analysis, Nissl staining, thioflavin-S staining, enzyme-linked immunosorbent assay, Golgi-Cox staining, transmission electron microscopy (TEM), immunofluorescence staining, proteomics, adenosine triphosphate (ATP) detection, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) assessment, mitochondrial morphology analysis, electrophysiological studies, western blotting, and molecular docking. The results revealed changes in synaptic currents, mitophagy, and mitochondrial dynamics in the AD models. Remarkably, intervention with Dengzhan Shengmai (DZSM) capsules emerged as a pivotal element in this investigation. Aβ 42 -induced synaptic dysfunction was significantly mitigated by DZSM intervention, which notably amplified the frequency and amplitude of synaptic transmission. The cognitive impairment observed in AD rats was ameliorated and accompanied by robust protection against structural damage in key brain regions, including the hippocampal CA3, primary cingular cortex, prelimbic system, and dysgranular insular cortex. DZSM intervention led to increased IDE levels, augmented LTP amplitude, and enhanced dendritic spine density and length. Moreover, DZSM intervention led to favourable changes in mitochondrial parameters, including ROS expression, MMP and ATP contents, and mitochondrial morphology. In conclusion, our findings delved into the realm of altered synaptic currents, mitophagy, and mitochondrial dynamics in AD, concurrently highlighting the therapeutic potential of DZSM intervention. Graphical abstract Download : Download high-res image (267KB) Download : Download full-size image

The Ameliorative Effects and Underlying Mechanisms of Dopamine D1-like Receptor Agonist SKF38393 on Aβ1–42-induced Cognitive Impairment

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice

DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model

The Effect and Molecular Mechanisms of SB239063 on Regulating Aβ Generation in APPswe/PS1dE9 Mice

Effect of Brain-Derived Neurotrophic Factor on Tyrosine Kinase B and Endogenous Brain-Derived Neurotrophic Factor Expressions by Lateral Ventricle Infusion into AD Mice

D5 Receptor Agonist 027075 Promotes Cognitive Function Recovery and Neurogenesis in a Aβ1-42-induced Mouse Model.

Complicated Function of Dopamine in Aβ-related Neurotoxicity: Dual Interactions with Tyr10 and SNK(26–28) of Aβ

The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta

DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice

Dopamine D2 receptor agonist Bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation in mice

DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway

The atypical dopamine receptor agonist SKF 83959 enhances hippocampal and prefrontal cortical neuronal network activity in a rat model of cognitive dysfunction

Dopamine D2 receptor agonist Bromocriptine ameliorates Aβ 1-42 -induced memory deficits and neuroinflammation in mice

The Effect of Dendrobium Nobile Lindl. Alkaloids on the Protein Expression of Aβ42,APP and BACE1 of Hippocampus in db/db Mice

Rescue of Cognitive Deficits in APP/PS1 Mice by Accelerating the Aggregation of Β-Amyloid Peptide

Altered synaptic currents, mitophagy, mitochondrial dynamics in Alzheimer's disease models and therapeutic potential of Dengzhan Shengmai Capsules intervention

GPR40 Receptor Activation Leads to CREB Phosphorylation and Improves Cognitive Performance in an Alzheimer’s Disease Mouse Model

Daphnetin Ameliorates Aβ Pathogenesis Via STAT3/GFAP Signaling in an APP/PS1 Double-Transgenic Mouse Model of Alzheimer's Disease.

SCM-198 Ameliorates Cognitive Deficits, Promotes Neuronal Survival and Enhances CREB/BDNF/TrkB Signaling without Affecting Aβ Burden in AβPP/PS1 Mice

Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.